Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05875532 · ClinicalTrials.gov registry record
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 34,960
- Enrollment target
NCT05875532: Completed study, sponsored by Boehringer Ingelheim.
NCT05875532 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 34,960 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05875532 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 34,960 participants
- Enrollment target
Study Summary
The primary objective for this trial is to investigate the incidence probability of progression to Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) in patients with fibrosing ILD other than Idiopathic Pulmonary Fibrosis (IPF) in real-world setting in Japan. The secondary objective is to investigate the characteristics of procedures for management and treatment in patients with fibrosing ILD other than IPF in real-world setting in Japan.
Primary Outcome
The cumulative incidence probability is the estimate of the risk a patient will experience by 6, 12, 18 and 24 months after the second diagnosis of fibrosing ILD (index date) of progression to PF-ILDs. It is the complement of the Kaplan-Meier estimates. The Greenwood's variance estimate was used to calculate the 95% confidence interval. Disease progression was defined as 3 or more pulmonary function tests within 365 days, 3 or more tomographies within 365 days, 1 or more claims for oxygen thera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34,960 participants |
| Start Date | 2023-04-20 |
| Est. Completion | 2023-05-01 |
What the finished NCT05875532 record still lists
NCT05875532 is an observational study that tracks outcomes without assigning an intervention. Its 34,960 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05875532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05875532 about?
NCT05875532 is a clinical study titled "Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment". The primary objective for this trial is to investigate the incidence probability of progression to Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) in patients with fibrosing ILD other than Idiopathic Pulmonary Fibrosis (IPF) in real-world setting in Japan. The secondary objective is to i...
What is the current status of trial NCT05875532?
This trial is currently completed. The enrollment target is 34,960 participants. The study started on 2023-04-20. Estimated completion is 2023-05-01.
Who is sponsoring clinical trial NCT05875532?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02225301 · 35,000 participants · NA
iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
- NCT03262259 · 36,000 participants · NA
Evaluation of Global Smart Drinking Goals Initiative
- NCT07150923 · 36,503 participants · NA
Supraglottic Airway for Resuscitation Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI